SAO · RDOR3.SA
Rede D'Or São Luiz S.A.
R$31.44-R$0.91 (-2.81%)
Rede D'Or São Luiz S.A.’s quoted price sits in the lower half of its reported 52-week range, 35.03% below the high.
Loading market information…
SAO · FLRY3.SA · BRL
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:08 PM UTC. Cached market data; not a live quote.
One-year closing-price history · BRL. Historical prices are not a forecast.
Fleury S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fleury S.A.’s forward annual dividend is R$0.80 per share, paid semi-annual. The forward yield is 3.93% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fleury S.A.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of R$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fleury S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fleury S.A., a Brazilian healthcare provider, along with its subsidiaries, delivers a broad spectrum of medical services. These offerings span diagnostics, various treatments, clinical analysis, health management, general medical care, orthopedics, and ophthalmology. The company organizes its operations into three primary segments: Diagnostic Medicine, Integrated Medicine, and Dental. Its service portfolio includes laboratory and imaging examinations, comprehensive diagnostic information, health check-ups, specialized reference laboratory functions, genomic testing, day clinic facilities, infusion centers, and dental imaging and radiology. Additionally, Fleury provides Saúde I, a digital health platform that facilitates teleconsultations, remote medical advice, online diagnostic exams, and virtual procedures. It further extends its services to corporate clients with tailored solutions, offers in-person primary care, and supports medical professionals through digital office tools and ongoing medical education.
Latest available per-share figures in BRL. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:23 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 7, 2025 |
| R$0.33-2.94% vs estimate |
| R$2.02B-0.43% vs estimate |
| Q4 2024 | Feb 27, 2025 | R$0.15-6.25% vs estimate | R$1.84B+0.28% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | R$0.35-2.78% vs estimate | R$1.96B+1.05% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
R$31.44-R$0.91 (-2.81%)
Rede D'Or São Luiz S.A.’s quoted price sits in the lower half of its reported 52-week range, 35.03% below the high.
R$14.17-R$0.60 (-4.06%)
Bradsaude S.A.’s quoted price sits in the upper half of its reported 52-week range, 14.48% below the high.
R$15.12-R$0.38 (-2.45%)
Raia Drogasil S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.86% below the high.
R$21.37-R$0.15 (-0.7%)
Hypera S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.77% below the high.
R$3.01+R$0.06 (+2.03%)
Diagnósticos da América S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.01% below the high.
R$9.15-R$0.20 (-2.14%)
Blau Farmacêutica S.A.’s quoted price sits in the lower half of its reported 52-week range, 36.9% below the high.
R$4.16-R$0.07 (-1.65%)
Hapvida Participações e Investimentos S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.31% below the high.
R$2.49+R$0.03 (+1.22%)
Allianca Saude e Participacoes S.A.’s quoted price sits in the lower half of its reported 52-week range, 59.77% below the high.
